Lilly packs up ulcerative colitis med for FDA with phase 3 success after ditching psoriasis
Eli Lilly will ask the FDA to approve its IL-23 drug mirikizumab in ulcerative colitis next year after passing a phase 3 test in the inflammatory bowel disease.







